Evidence map›Paper›PMID 35202479›Full record

ReviewAllergy2022

Managing the allergy and asthma epidemic in 2020s-Lessons from the Finnish experience.

Tari Haahtela, Juha Jantunen, Kimmo Saarinen, Erja Tommila, Erkka Valovirta, Tuula Vasankari, Mika J Mäkelä

Open access · hybridAbstract readReview
In one paragraph

Review in Allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Allergy prevention-a new public health perspective.European journal of public health · 2026
    Article
  4. Nature prescription for patients with chronic respiratory diseases.The World Allergy Organization journal · 2026
    Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Role of Small Molecule Ligands in IgE-Mediated Allergy.Current allergy and asthma reports · 2023
    Review
  15. Review
  16. Review
  17. Article
  18. Pneumo news · 2022
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Tari HaahtelaSkin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-4757-2156
Juha JantunenAllergy, Skin and Asthma Federation, Helsinki, Finland.ORCID 0000-0003-0250-4424
Kimmo SaarinenAllergy, Skin and Asthma Federation, Helsinki, Finland.
Erja TommilaFinnish Lung Health Association (FILHA), Helsinki, Finland.
Erkka ValovirtaDepartment of Lung Diseases and Clinical Allergology, University of Turku, and Allergy Clinic, Terveystalo, Turku, Finland.
Tuula VasankariFinnish Lung Health Association (FILHA), Helsinki, Finland.
Mika J MäkeläSkin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Allergy and Asthma Federation · FIFinnish Lung Health Association · FIUniversity of Helsinki · FIUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Finland, a systematic public health programme was implemented from 2008 to 2018 to mitigate the burden of allergic disorders by revisiting the prevention strategy. Allergy health and contacts with natural environment were emphasized to promote immunological and psychological resilience instead of poorly justified avoidance. Allergy management practices were improved and low-valued recommendations for care, for example for food allergy, were revised. Patients and families were empowered to use guided self-management to proactively stop symptom exacerbations. A professional non-governmental organization implemented the nationwide education for healthcare and patient NGOs for patients, families and lay public. In healthcare, the work supporting allergic patients and families was organized towards common goals and integrated into everyday work without extra costs. Reaching the predefined goals was followed by employing the national healthcare registers and questionnaire surveys. Governmental bodies contributed with kick-off funding, which was supplemented by private funding. International collaboration, for example with the European patient organization (EFA), increased awareness of the Finnish action and predisposed it for peer review. The 10-year results are favourable, patients are less disabled, practices and attitudes in healthcare have changed, and major cost savings have been obtained. Views of the lay public and patients are slow to move, however. Local multidisciplinary allergy teams were set up to continue the activities also after the Programme. Changes in environment and lifestyle in the last 50 years are the main reasons for the allergy rise. The Finnish experience may help to manage allergic diseases, improve nature relatedness in the fast-urbanizing world, combat nature loss and reduce the disease burden.

Indexed as

AsthmaFood HypersensitivityCost of IllnessDisease SusceptibilityFinlandHumansallergy campaignallergy epidemicallergy preventionallergy programmebiodiversitypublic health

Identifiers

PMID35202479
PMCPMC9546028
OpenAlexW4213420203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.